REVOLUTION MEDICINES INC (RVMD)

Top movers in Tuesday's after hours session

Get insights into the top gainers and losers of Tuesday's after-hours session.

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond...

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that...

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time...

First Week of September 20th Options Trading For Revolution Medicines (RVMD)

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel...

Commit To Buy Revolution Medicines At $24, Earn 14.1% Annualized Using Options

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.

3 Biotech Stocks That Could Boom or Bust by 2025

Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday.

Raymond James starts coverage of Revolution Medicines at outperform (NASDAQ:RVMD)

Raymond James initiated coverage of Revolution Medicines (RVMD) with an outperform rating, citing optimism about the company's drug candidate RMC-6236. The inve

Revolution Medicines Completes Acquisition of EQRx

Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON)...

Commit To Buy Revolution Medicines At $14, Earn 13.3% Annualized Using Options

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

Transaction on Track to Close in November 2023...

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112...

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel...

Why Revolution Medicines Stock Is Crashing Today

Investors were disappointed by Revolution Medicines' data, presented at ESMO.

Revolution Medicines Crashes 39% On Lackluster Test Results In Cancer Treatment

The results were "at best, in line" with expectations for lung and pancreatic cancer treatment.

Revolution Medicines stock falls on data for cancer therapy

Revolution Medicines (RVMD) shares plummeted 34% due to Phase 1/1b trial data for RMC-6236, an experimental therapy for lung and pancreatic cancer. Read more here.